Now showing items 1-4 of 4
Serum osteoprotegerin and renal function in the general population: The Tromsø Study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-03)
<p><i>Background</i>: Serum osteoprotegerin (OPG) is elevated in patients with chronic kidney disease (CKD) and increases with decreasing renal function. However, there are limited data regarding the association between OPG and renal function in the general population. The aim of the present study was to explore the relation between serum OPG and renal function in subjects recruited from the general ...
Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2014)
Hyperglycemia, Assessed by HbA1c, and Future Risk of Venous Thromboembolism - The Tromsø Study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2014-03-05)
Background: Glycated hemoglobin (HbA1c), a marker of average plasma glucose during the last 8-12 weeks, is associated with future risk of cardiovascular disease (CVD) and all-cause mortality. Objectives: To examine the association between hyperglycemia, assessed by HbA1c, and future risk of VTE in a population based cohort. Methods: HbA1c was measured in 16 156 unique subjects (25-87 years) ...
Myocardial infarction and future risk of cancer in the general population—the Tromsø Study
(Journal article; Tidsskriftartikkel; Peer reviewed, 2017-02-07)
The association between myocardial infarction (MI) and future risk of incident cancer is scarcely investigated. Therefore, we aimed to study the risk of cancer after a first time MI in a large cohort recruited from a general population. Participants in a large population-based study without a previous history of MI or cancer (n = 28,763) were included and followed from baseline to date of cancer, ...